AR077155A1 - Nanodispersion, nanoparticulas y solucion - Google Patents

Nanodispersion, nanoparticulas y solucion

Info

Publication number
AR077155A1
AR077155A1 ARP100102179A ARP100102179A AR077155A1 AR 077155 A1 AR077155 A1 AR 077155A1 AR P100102179 A ARP100102179 A AR P100102179A AR P100102179 A ARP100102179 A AR P100102179A AR 077155 A1 AR077155 A1 AR 077155A1
Authority
AR
Argentina
Prior art keywords
nanoparticles
nanodispersion
salts
solution
tacrolimus
Prior art date
Application number
ARP100102179A
Other languages
English (en)
Inventor
Ajay Jaysingh Khopade
N Arulsudar
Subhas Balaram Bhowmick
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of AR077155A1 publication Critical patent/AR077155A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Una nanodispersion estable que comprende nanopartículas que tienen un tamano promedio menor de 300 nm dispersadas en un vehículo que comprende un solvente miscible en agua y agua, comprendiendo dichas nanopartículas una o más drogas que tienen, un polímero y un surfactante que comprende una mezcla de ácidos grasos o sus sales y esterol o sus derivados o sus sales. Reivindicacion 2: Una nanodispersion en la forma reivindicada en la reivindicacion 1 en donde la droga se selecciona de un grupo que consiste de temsirolimus, tacrolimus, sirolimus, fenofibrato, ciclosporina, tacrolimus, brinzolamida o sus sales farmacéuticamente aceptables.
ARP100102179A 2009-06-19 2010-06-22 Nanodispersion, nanoparticulas y solucion AR077155A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1468MU2009 2009-06-19

Publications (1)

Publication Number Publication Date
AR077155A1 true AR077155A1 (es) 2011-08-03

Family

ID=43355961

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102179A AR077155A1 (es) 2009-06-19 2010-06-22 Nanodispersion, nanoparticulas y solucion

Country Status (12)

Country Link
US (1) US8778364B2 (es)
EP (1) EP2442805A4 (es)
JP (1) JP5627039B2 (es)
KR (1) KR20120050414A (es)
CN (1) CN102802624A (es)
AR (1) AR077155A1 (es)
AU (1) AU2010261342A1 (es)
CA (1) CA2765541A1 (es)
EA (1) EA201270050A1 (es)
MX (1) MX2011013726A (es)
WO (1) WO2010146606A1 (es)
ZA (1) ZA201109510B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012028037A2 (pt) 2010-05-03 2016-08-02 Teikoku Pharma Usa Inc formulação de pró-emulsão líquida de taxano não aquosa, métodos para administrar um taxano a um paciente e para fabricar uma formulação de pró-emulsão de taxano, composição de emulsão de taxano, e, kit
ES2661978T3 (es) 2010-05-26 2018-04-04 Selecta Biosciences, Inc. Vacunas multivalentes de nanovehículos sintéticos
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
CN104105472A (zh) 2011-12-20 2014-10-15 维奥姆生物科学有限公司 用于治疗真菌感染的局部油组合物
CN103483353B (zh) * 2012-06-13 2016-02-24 上海现代药物制剂工程研究中心有限公司 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
AU2014252157B2 (en) * 2013-04-12 2017-05-11 Vyome Therapeutics Limited Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
AU2015246030B2 (en) * 2014-04-09 2020-03-12 Pulse Pharmaceuticals Pvt Ltd Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
WO2015184238A1 (en) * 2014-05-30 2015-12-03 Oms Investments, Inc. Nano-sized water-based dispersion compositions and methods of making thereof
CN104798772B (zh) * 2015-03-13 2017-05-24 中国农业科学院农业环境与可持续发展研究所 一种农药纳米固体分散体及其制备方法
JP2018516964A (ja) 2015-06-09 2018-06-28 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドSun Pharma Advanced Research Company Limited 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法
EP3334416A1 (en) 2015-08-11 2018-06-20 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017129772A1 (en) * 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN114749656A (zh) * 2020-12-28 2022-07-15 航天神舟生物科技集团有限公司 一种金属纳米铁/纳米铜粒子溶液及工作液的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AU1809499A (en) 1997-12-10 1999-06-28 Awadhesh K. Mishra Self-emulsifying fenofibrate formulations
KR19990075621A (ko) 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
AU7599900A (en) 1999-09-23 2001-04-24 Dabur Research Foundation Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles
AU7638200A (en) 1999-10-20 2001-04-30 Vesifact Ag Microemulsion preconcentrates which contain cyclosporines and corresponding microemulsions
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
TWI230616B (en) 2000-09-25 2005-04-11 Ind Tech Res Inst Liposome for incorporating large amounts of hydrophobic substances
EP1387676A2 (en) 2001-05-01 2004-02-11 Angiotech Pharmaceuticals, Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US20040005339A1 (en) 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
ITMI20022323A1 (it) 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20050288521A1 (en) 2004-06-29 2005-12-29 Phytogen Life Sciences Inc. Semi-synthetic conversion of paclitaxel to docetaxel
WO2006066063A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
BRPI0608173A2 (pt) * 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
US20090118354A1 (en) 2005-06-17 2009-05-07 Mayne Pharma Limited Liquid Pharmaceutical Formulations of Docetaxel
CA2626016A1 (en) 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
PT2076244T (pt) 2006-10-10 2017-03-09 Jina Pharmaceuticals Inc Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos
US20100068251A1 (en) 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
WO2008144355A2 (en) 2007-05-17 2008-11-27 Morton Grove Pharmaceuticals, Inc. Stable, self-microemulsifying fenofibrate compositions
CN101909614B (zh) * 2007-12-24 2015-04-15 太阳医药高级研发有限公司 纳米分散体
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound

Also Published As

Publication number Publication date
JP5627039B2 (ja) 2014-11-19
WO2010146606A1 (en) 2010-12-23
EP2442805A4 (en) 2012-11-21
EA201270050A1 (ru) 2012-05-30
US20120087959A1 (en) 2012-04-12
JP2012530694A (ja) 2012-12-06
CN102802624A (zh) 2012-11-28
KR20120050414A (ko) 2012-05-18
US8778364B2 (en) 2014-07-15
CA2765541A1 (en) 2010-12-23
ZA201109510B (en) 2012-09-26
AU2010261342A1 (en) 2012-01-19
MX2011013726A (es) 2012-02-29
EP2442805A1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
AR077155A1 (es) Nanodispersion, nanoparticulas y solucion
CO6290681A2 (es) Nanodispersion
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ES2623233T3 (es) Composición farmacéutica tópica a base de alcanos semifluorados
CL2011002053A1 (es) Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel.
AR072668A1 (es) Encapsulacion de agentes biologicamente activos
AR059829A1 (es) Sistemas estables de nanocapsulas para la administracion de moleculas activas
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
BRPI0810899A2 (pt) Formulação de nanopartículas de plga ativadas carregadas com agente ativo para substâncias nano-terapêuticas anticâncer direcionais.
EP4218724A3 (en) Microstructure array for delivery of active agents
AR071239A1 (es) Microesferas que tienen una estructura de nucleo / recubrimiento que comprenden aripiprazol y uso
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
ES2664584B2 (es) Nanoparticulas con interiores protegidos, y métodos de uso de las mismas
HRP20201179T4 (hr) Pripravci s kontinuiranim oslobađanjem na bazi nevodenih nosača
AR065539A1 (es) Composiciones farmaceuticas que comprenden nanoparticulas que comprenden polimeros entericos y caseina
Shang et al. Recent advances on transdermal delivery systems for the treatment of arthritic injuries: From classical treatment to nanomedicines
BR112012015016B8 (pt) formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
BR112012004967B8 (pt) forma de dosagem oral, compreendendo pelo menos um agente biologicamente ativo, substâncias auxiliares da formulação e partículas magnetizáveis, seu uso e seu método de produção
AR081520A1 (es) Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo
Dehshahri et al. New horizons in hydrogels for methotrexate delivery
AR092840A1 (es) Elaboracion de degarelix
BRPI0418294A (pt) composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes
Yadava et al. Curcumin-loaded nanostructure hybrid lipid capsules for co-eradication of breast cancer and cancer stem cells with enhanced anticancer efficacy

Legal Events

Date Code Title Description
FB Suspension of granting procedure